Tech Company Financing Transactions
March Biosciences Funding Round
Cancer Focus Fund joined a $4.8 million capital raise for March Biosciences. The funding round closed on 11/9/2023.
Transaction Overview
Company Name
Announced On
11/9/2023
Transaction Type
Venture Equity
Amount
$4,800,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate its upcoming Phase 2 clinical trial of MB-105 for the treatment of relapsed T-cell leukemias and lymphomas.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2450 Holcombe boulevard X37
Houston, TX 77021
USA
Houston, TX 77021
USA
Phone
Undisclosed
Website
Email Address
Overview
March Biosciences, Inc is a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies. March Bio's lead asset is at the end of Phase I trials for T-cell malignancies, diseases with a dismal prognosis that is currently unaddressed by CAR-T and targeted therapy technologies. The company's pipeline is designed to expand on these early successes to more broadly impact other high-challenge cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sarah Hein
Co-Founder
Max Mamonkin
Browse more venture capital transactions:
Prev: 11/9/2023: Elucid venture capital transaction
Next: 11/9/2023: Evolv Technologies venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs